Zoetis Faces Shareholder Lawsuit Over Alleged Misleading Performance Data

The lawsuit, filed in the Southern District of New York by the City of Ann Arbor Retiree Health Care Benefit Plan & Trust, alleges that Zoetis executives violated the Securities Exchange Act of 1934. According to the complaint, the company failed to disclose that its flagship products—Librela, Apoquel, Cytopoint, and Simparica Trio—were losing market share to cheaper competitors or facing safety concerns. Specifically, plaintiffs argue that veterinarians became increasingly cautious toward Librela following FDA warnings about neurological complications in dogs, a trend the company allegedly downplayed.

The impact on the company’s valuation was stark over a series of quarterly disclosures. Following an August 2025 report of weakening demand, shares fell nearly 4%. Subsequent reports in November 2025 and February 2026 triggered further slides, culminating in a 21% drop on May 7, 2026, when Zoetis reported slowing revenue growth and worsening performance in its dermatology and parasiticide franchises. Robbins Geller Rudman & Dowd LLP, the firm representing the class, is now seeking investors with substantial losses to step forward as lead plaintiffs by the July deadline.